11C-ARMI for Healthy Subjects

This trial tests a new radioactive tracer called 11C-ARMI in healthy individuals. The tracer, a special type of drug, helps researchers visualize chemicals in the body during imaging scans, potentially aiding in the study of diseases like Alzheimer's and Parkinson's. Participants will undergo PET/CT scans, and some may also have MRI scans to evaluate the tracer's effectiveness. Ideal candidates are healthy individuals who have been screened under specific protocols and can complete all study procedures. As a Phase 1 trial, this research focuses on understanding the tracer's function in people, offering participants the unique opportunity to be among the first to receive this new treatment.

Yes, you must stop taking medications that significantly bind to alpha-1 adrenoceptors, alter norepinephrine release, or lower blood pressure, including certain blood pressure medications and erectile dysfunction drugs, within five elimination half-lives before the PET scan.

In this trial, researchers are testing a new substance called 11C-ARMI. No specific safety information from past studies exists for 11C-ARMI itself. As a Phase 1 trial, this marks the first time the treatment is tested in humans. Phase 1 trials primarily focus on safety, so researchers exercise great caution. They closely monitor participants for any side effects or unexpected reactions.

Researchers are excited about the 11C-ARMI trial because it explores a novel imaging technique rather than a treatment. Unlike traditional imaging methods used for diagnostic purposes, 11C-ARMI is designed to enhance the visualization of biological processes at a molecular level in healthy individuals. This approach could provide unprecedented insights into how the human body functions in real time, potentially leading to breakthroughs in understanding various conditions and developing new diagnostic tools. By focusing on healthy subjects, the trial aims to establish a baseline of normal biological activity, which is crucial for identifying abnormalities in disease states.

Research has shown that 11C-ARMI is a new type of radioactive substance used in imaging scans. While direct evidence of its effectiveness for diseases like Alzheimer's or Parkinson's is not yet available, this tracer is being developed to highlight specific chemicals in the body. This development could enhance understanding of these conditions. Tracers like 11C-ARMI attach to certain molecules, making them visible in scans, which is crucial for diagnosing and studying diseases. In this trial, all participants will undergo the same tests to assess the safety of 11C-ARMI and its visibility in the body.⁶⁷⁸⁹¹⁰